Clinical trial

Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

NCT01217697

StatusAPPROVED_FOR_MARKETING

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Study timeline

Registry last updated2017-03-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Neoplasmsunresolved

Genital Neoplasms, Maleunresolved

Urogenital Neoplasmsunresolved

Genital Diseases, Maleunresolved

Interventions

Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate

Prednisone\PrednisoloneDRUG

Sponsors & collaborators

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.lead sponsor

Mapped research locations

New YorkNew York, United States1 HoustonTexas, United States1 BostonMassachusetts, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 AtlantaGeorgia, United States1 MiamiFlorida, United States1 TorontoOntario, Canada1 San AntonioTexas, United States1 NashvilleTennessee, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01217697 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.